Reviews Semax

Semax References: The Cited Literature

The cited Semax literature

Every quantitative claim on this site maps to one of the citations below. The list is organized by topic — origin and structure, mechanism and BDNF/NGF work, ischemia and stroke trials, pharmacokinetics, monoaminergic effects, modified analogs, recent 2020-2025 transcriptomic and proteomic work, and the secondary clinical record. Russian-language journal entries are identified by PubMed PMID where DOI assignment pre-dates the index. The full bibliographic detail (title, authors, journal, year, DOI or PMID URL) is rendered in the references table below.

  1. Potaman VN, Antonova LV, Dubynin VA, Zaitzev DA, Kamensky AA, Myasoedov NF, Nezavibatko VN. Entry of the synthetic ACTH(4-10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;127(1):133-136. ↗
  2. Ashmarin IP. Anticipated and unexpected physiological effects of oligopeptides (glyprolines, ACTH(4-10) analogs, taftsin, and thyroliberin). Ross Fiziol Zh Im I M Sechenova. 2001;87(11):1471-1476. ↗
  3. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. ↗
  4. Shadrina M, Kolomin T, Agapova T, Agniullin Y, Shram S, Slominsky P, Lymborska S, Myasoedov N. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. ↗
  5. Bashkatova V, Koshelev V, Fadyukova O, Alexeev A, Vanin A, Rayevsky K, Asmus F, Allikmets L. Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Res. 2001;894(1):145-149. ↗
  6. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. ↗
  7. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibatko VN, Zhuravleva EI, Vanichkin AV. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. ↗
  8. Miasoedova NF, Skvortsova VI, Nasonov EL, Zhuravleva EIu, Grivennikov IA, Arsen'eva EL, Sukhanov II. Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(5):15-19. ↗
  9. Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):15-18. ↗
  10. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. ↗
  11. Romanova GA, Silachev DN, Shakova FM, Kvashennikova YN, Viktorov IV, Shram SI, Myasoedov NF. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bull Exp Biol Med. 2006;142(6):663-666. ↗
  12. Safarova ER, Shram SI, Zolotarev YA, Myasoedov NF. Effect of Semax peptide on survival of cultured rat pheochromocytoma cells during oxidative stress. Bull Exp Biol Med. 2003;135(3):268-271. ↗
  13. Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim. 2006;32(1):64-70. ↗
  14. Mao Y, et al. Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. ↗
  15. Radchenko EV, et al. The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons. Bull Exp Biol Med. 2025. ↗
  16. Filippenkov IB, Stavchansky VV, Denisova AE, Yuzhakov VV, Sevan'kaeva LE, Sudarkina OY, Dmitrieva VG, Gubsky LV, Myasoedov NF, Limborska SA, Dergunova LV. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel). 2020;11(6):681. ↗
  17. Stavchansky VV, Yuzhakov VV, Botsina AY, Skvortsova VI, Bondurko LN, Tsyganova MG, Limborska SA, Myasoedov NF, Dergunova LV. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. Int J Mol Sci. 2021;22(12):6179. ↗
  18. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. ↗
  19. Tsai SJ. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(5):1144-1146. ↗
  20. Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Pharmacokinetics of Semax in rats: brain and blood distribution after intranasal administration. Russ J Bioorg Chem. 2006;32(1):64-70. ↗
  21. Russian State Pharmacopeia entry — Semax 0.1% and 1% intranasal solution. Federal Service for Surveillance in Healthcare (Roszdravnadzor). Registered indications and dosing for ischemic stroke recovery, cognitive disorders, and optic nerve disease. ↗
  22. Kaplan AYa, Kochetova AG, Nezavibatko VN, Ryasina TV, Ashmarin IP. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. ↗
  23. Kaplan AYa, Kochetova AG, Nezavibatko VN, Rjasina TV, Ashmarin IP. Effect of the heptapeptide Semax on the human electroencephalogram. Zh Vyssh Nerv Deiat Im I P Pavlova. 1996;46(2):334-338. ↗
  24. Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA. Therapeutic effect of intranasal and endonasal-electrophoresis Semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):15-18. ↗